目次

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Overview
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Companies Involved in Therapeutics Development
AstraZeneca Plc
Clementia Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Incyte Corp
Ipsen SA
La Jolla Pharmaceutical Company
Pfizer Inc
Regeneron Pharmaceuticals Inc
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Drug Profiles
dipyridamole - Drug Profile
Product Description
Mechanism Of Action
DS-6016 - Drug Profile
Product Description
Mechanism Of Action
garetosmab - Drug Profile
Product Description
Mechanism Of Action
INCB-00928 - Drug Profile
Product Description
Mechanism Of Action
IPN-60130 - Drug Profile
Product Description
Mechanism Of Action
palovarotene - Drug Profile
Product Description
Mechanism Of Action
saracatinib difumarate - Drug Profile
Product Description
Mechanism Of Action
sirolimus - Drug Profile
Product Description
Mechanism Of Action
Small Molecule 1 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
Small Molecule 2 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
trevogrumab - Drug Profile
Product Description
Mechanism Of Action
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Dormant Projects
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Discontinued Products
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Product Development Milestones
Featured News & Press Releases
Oct 25, 2022: Ipsen statement on updated timeline for palovarotene FDA Advisory Committee meeting
Jun 29, 2022: Ipsen announces U.S. FDA priority review for palovarotene new drug application in patients with fibrodysplasia ossificans progressiva following resubmission
Jan 24, 2022: Health Canada approves Ipsen’s Sohonos (palovarotene capsules) as the first approved treatment for Fibrodysplasia Ossificans Progressiva
Aug 13, 2021: Ipsen announces withdrawal of palovarotene NDA, confirming intention to re-submit following additional data analyses
May 28, 2021: Ipsen confirms U.S. FDA accepts new drug application for Palovarotene as the first potential treatment worldwide for fibrodysplasia ossificans progressiva (FOP)
Oct 30, 2020: Regeneron provides update on the Garetosmab phase 2 LUMINA-1 trial in fibrodysplasia ossificans progressiva (FOP)
Sep 10, 2020: Ipsen to present new Insights at ASBMR for potential treatment of ultra-rare disease Fibrodysplasia Ossificans Progressiva (FOP), including global phase III MOVE Trial results
Aug 25, 2020: Ipsen to present results from MOVE, the first global phase III trial in fibrodysplasia ossificans progressiva (FOP), at ASBMR 2020 annual meeting
Mar 27, 2020: Ipsen to restart dosing of palovarotene in FOP studies
Jan 27, 2020: Ipsen temporarily stops palovarotene dosing in FOP trials
Jan 10, 2020: Regeneron reports positive data from rare bone disease trials
Jan 09, 2020: Regeneron announces encouraging garetosmab phase 2 results in patients with ultra-rare debilitating bone disease
Dec 09, 2019: Ipsen initiates partial clinical hold for palovarotene IND120181 and IND135403 studies
Mar 27, 2019: Blueprint Medicines provides update on clinical progress of BLU-782
Feb 11, 2019: Clementia granted Rare Pediatric Disease Designation by FDA for Palovarotene for Fibrodysplasia Ossificans Progressiva
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by AstraZeneca Plc, 2022
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Clementia Pharmaceuticals Inc, 2022
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Daiichi Sankyo Co Ltd, 2022
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Incyte Corp, 2022
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Ipsen SA, 2022
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by La Jolla Pharmaceutical Company, 2022
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Pfizer Inc, 2022
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Dormant Projects, 2022
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Discontinued Products, 2022

List of Figures
Number of Products under Development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022